Skip to content

Type 2 diabetes — incretin therapies

TL;DR — GLP-1 receptor agonists lower HbA1c and weight and, for several molecules, major cardiovascular events; a nine-trial meta-analysis found class-level reductions in cardiovascular, mortality and kidney outcomes (Kristensen 2019, PMID 31422062). Tirzepatide, a GIP/GLP-1 co-agonist, lowered HbA1c by up to 2.30 percentage points in SURPASS-2 and produced weight loss approaching obesity-surgery territory in separate trials (Frías 2021, PMID 34170647; Jastreboff 2022, PMID 35658024). FLOW established a kidney-outcome benefit for semaglutide in T2D with CKD (Perkovic 2024, PMID 38785209). Gastrointestinal intolerance, gallbladder events, lean-mass loss, discontinuation, cost and access determine real-world value.

Drug families

Family Examples Receptor action Main clinical axes
GLP-1RA liraglutide, dulaglutide, semaglutide GLP-1 Glycaemia, satiety, weight, CV outcomes
Short-acting GLP-1RA exenatide, lixisenatide GLP-1 Strong postprandial effect; neutral CVOTs
Dual agonist tirzepatide GIP + GLP-1 Greater mean HbA1c/weight effect
Emerging co-agonists retatrutide, CagriSema, survodutide Multiple peptide pathways Phase 3/outcome programmes ongoing

Cardiovascular outcome evidence

Trial Agent Population MACE result
LEADER liraglutide T2D, high CV risk HR 0.87; CV death HR 0.78 (Marso 2016, PMID 27295427)
SUSTAIN-6 semaglutide T2D, high CV risk MACE noninferiority and superiority signal; retinopathy warning (Marso 2016, PMID 27633186)
REWIND dulaglutide T2D with/without prior CVD 12.0% vs 13.4%; HR 0.88 (0.79–0.99) (Gerstein 2019, PMID 31189511)
EXSCEL exenatide weekly Broad T2D CV-risk population Noninferior, not superior for MACE (Holman 2017, PMID 28910237)
HARMONY Outcomes albiglutide T2D with CVD Reduced MACE (Hernandez 2018, PMID 30291013)
PIONEER 6 oral semaglutide T2D, high CV risk CV safety established (Husain 2019, PMID 31185157)
SELECT semaglutide 2.4 mg Obesity + CVD, no diabetes MACE HR 0.80 (Lincoff 2023, PMID 37952131)

The 2019 meta-analysis found GLP-1RA reductions across MACE, CV death, all-cause mortality and kidney outcomes, but molecules and populations differed (Kristensen 2019, PMID 31422062). A larger network meta-analysis found GLP-1RA relatively stronger for stroke and SGLT2 inhibitors for heart-failure hospitalisation (Palmer 2021, PMID 33441402).

Glycaemia and weight

Study Comparison Quantitative anchor
SURPASS-2 Tirzepatide 5/10/15 mg vs semaglutide 1 mg HbA1c fell up to 2.30 percentage points; tirzepatide superior at all doses (Frías 2021, PMID 34170647)
SURMOUNT-1 Tirzepatide in obesity without diabetes Mean weight −20.9% at 15 mg over 72 weeks (Jastreboff 2022, PMID 35658024)
SURMOUNT-2 Tirzepatide in obesity with T2D Large weight and HbA1c reductions, smaller weight loss than non-diabetes trial (Garvey 2023, PMID 37385275)
Obesity head-to-head Tirzepatide vs semaglutide Tirzepatide produced greater weight loss (Aronne 2025, PMID 40353578)

Kidney outcomes

LEADER secondary analysis showed fewer composite kidney outcomes with liraglutide, driven largely by albuminuria (Mann 2017, PMID 28854085). FLOW moved beyond a secondary signal: semaglutide reduced kidney-disease progression in people with T2D and CKD (Perkovic 2024, PMID 38785209).

Kidney evidence Status Interpretation
Albuminuria changes Common secondary endpoint Useful risk marker, not kidney failure itself
eGFR slope Supportive intermediate Sensitive to acute and chronic effects
FLOW primary outcome Dedicated kidney CVOT Establishes organ protection in T2D+CKD (Perkovic 2024, PMID 38785209)

Adverse effects and cautions

Issue Evidence/management implication
Nausea, vomiting, diarrhoea Dose-related; slow titration and discontinuation common
Gallbladder disease Increased with rapid weight loss and some GLP-1RA exposure
Pancreatitis Rare signal; causal magnitude remains difficult to establish
Retinopathy worsening SUSTAIN-6 signal concentrated with rapid HbA1c improvement and baseline disease (Marso 2016, PMID 27633186)
Lean-mass loss Some fraction of lost weight; function and protein/resistance exercise matter
Hypoglycaemia Low alone; rises with insulin or sulfonylurea
Pregnancy Not a weight-loss/diabetes treatment during pregnancy
Anaesthesia Delayed gastric emptying has procedural implications

Discontinuation and access

These are chronic therapies. Benefits that depend on appetite suppression and continued exposure are expected to attenuate after withdrawal; remission definitions explicitly exclude on-drug normoglycaemia (Riddle 2021, PMID 34462270).

Cost-effectiveness depends on baseline CV/kidney risk, price, adherence and duration. A 536.6-million-person disease cannot be modelled as though every eligible patient has equal access (Sun 2022, PMID 34879977).

Initiation and response framework

Step Measure Reason
Baseline HbA1c, weight, kidney function, eye/GI history Benefit and safety context
Start low/titrate Symptoms and intake Reduce GI discontinuation
Early review Hydration, nausea, glucose, hypoglycaemia Adjust insulin/secretagogue
Medium review HbA1c, weight, function, persistence Confirm meaningful benefit
Long-term CV/kidney outcomes, gallbladder, access Chronic net value

Interpreting weight loss

Mean percentage loss hides a wide response distribution. Trials should report categorical thresholds, discontinuation, regain and function, not only mean change. Weight loss in T2D is often smaller than in parallel obesity trials, so indirect comparisons require matched populations (Garvey 2023, PMID 37385275; Jastreboff 2022, PMID 35658024).

Combination with insulin or SGLT2 therapy

Combination Potential gain Main control
GLP-1RA + basal insulin Lower meal glucose/weight, less insulin escalation Proactive low-glucose review
GLP-1RA + SGLT2 Complementary MACE/HF/CKD/weight profile Cost and direct combination-outcome gap
Tirzepatide + insulin Strong HbA1c/weight effect Insulin dose and GI monitoring

Evidence boundaries

  • A cardiovascular benefit is molecule- and trial-supported, not automatically proven for every co-agonist.
  • Obesity trials without diabetes cannot supply a T2D kidney-effect estimate.
  • HbA1c below 6.5% on therapy is controlled disease, not consensus remission.
  • Short trials cannot establish safety for decades of exposure.
  • Supply-constrained discontinuation is part of effectiveness, even if absent from efficacy estimands.

Minimum comparative outcome set

Future head-to-head studies should report HbA1c, weight distribution, MACE, HF, kidney outcomes, retinopathy, gallbladder/pancreatic events, lean mass/function, discontinuation, regain and total cost using identical definitions across arms.

A prespecified SURPASS meta-analysis established cardiovascular safety before a dedicated active-comparator CVOT matured (Sattar 2022, PMID 35210595).

Pipeline verified at ClinicalTrials.gov

Programme Registration Live status on 2026-08-30
SURPASS-CVOT NCT04255433 Completed
SOUL oral semaglutide CVOT NCT03914326 Completed
Retatrutide obesity/CVD NCT05882045 Completed
TRIUMPH-Outcomes retatrutide NCT06383390 Active, not recruiting
CagriSema REDEFINE 3 NCT05669755 Active, not recruiting
Tirzepatide CKD/obesity NCT05536804 Active, not recruiting

Cross-domain evidence crosswalk

These adjacent studies constrain interpretation of this page and make explicit where its conclusions depend on prevention, organ-outcome, remission, burden or implementation evidence.

Verified evidence anchor Connection
(Zinman 2015, PMID 26378978) Zinman B, et al. Empagliflozin Cardiovascular Outcomes. N Engl J Med. 2015
(Perkovic 2019, PMID 30990260) Perkovic V, et al. Canagliflozin Renal Outcomes. N Engl J Med. 2019
(Wiviott 2019, PMID 30415602) Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019
(Heerspink 2020, PMID 32970396) Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020
(EMPA-KIDNEY 2023, PMID 36331190) EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023
(Schauer 2017, PMID 28199805) Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes: 5-Year Outcomes. N Engl J Med. 2017

Outcome evidence is molecule- and comparator-specific

Trial Comparison/population Primary result What it does not prove
ELIXA Lixisenatide vs placebo after recent ACS; n=6,068 13.4% vs 13.2%; HR 1.02 (95% CI 0.89–1.17): noninferior, not superior A class-wide absence of benefit (Pfeffer 2015, PMID 26630143)
AMPLITUDE-O Efpeglenatide vs placebo; T2D with CVD/CKD; n=4,076 MACE 7.0% vs 9.2%; HR 0.73 (0.58–0.92); renal composite HR 0.68 (0.57–0.79) Dedicated kidney-failure benefit because macroalbuminuria was included (Gerstein 2021, PMID 34215025)
SOUL Oral semaglutide vs placebo; n=9,650 MACE 12.0% vs 13.8%; HR 0.86 (0.77–0.96) Superiority for its confirmatory kidney composite, which was nonsignificant (McGuire 2025, PMID 40162642)
SURPASS-CVOT Tirzepatide vs dulaglutide; modified n=13,165 MACE 12.2% vs 13.1%; HR 0.92 (95.3% CI 0.83–1.01): noninferior, not superior Superiority to an established GLP-1RA (Nicholls 2025, PMID 41406444)

Across ten long-acting GLP-1RA outcome trials (71,351 participants), updated meta-analysis found MACE HR 0.86 (95% CI 0.81–0.90), HF hospitalisation HR 0.86 (0.79–0.93), kidney composite HR 0.83 (0.75–0.92) and all-cause mortality HR 0.88 (0.82–0.93), without route heterogeneity between oral and injectable agents (Lee 2025, PMID 40156846). This supports a long-acting-class effect while retaining important variation in molecule, endpoint definition and population.

Glycaemic and weight efficacy across disease stages

SURPASS-1 enrolled injection-naive participants controlled by diet/exercise. At 40 weeks, tirzepatide reduced HbA1c by 1.87–2.07 percentage points versus +0.04 with placebo and weight by 7.0–9.5 kg; 31%–52% reached HbA1c <5.7%, but this was on medication and therefore not remission (Rosenstock 2021, PMID 34186022). When added to titrated basal insulin in SURPASS-5, HbA1c fell 2.11–2.40 points and weight changed −5.4 to −8.8 kg versus +1.6 kg with placebo; discontinuation rose from 10% at 5 mg to 18% at 15 mg versus 3% with placebo (Dahl 2022, PMID 35133415).

Combination evidence: supportive, not definitive

AMPLITUDE-O included 618 baseline SGLT2-inhibitor users. Efpeglenatide effects appeared consistent with and without SGLT2 therapy: MACE HR 0.70 (95% CI 0.37–1.30) versus 0.74 (0.58–0.94), and renal-composite HR 0.52 (0.33–0.83) versus 0.70 (0.59–0.83) (Lam 2022, PMID 34775781). SOUL likewise found no interaction: oral semaglutide MACE HR 0.89 (0.71–1.11) with baseline SGLT2 use and 0.84 (0.74–0.95) without (P-interaction=0.66) (Marx 2025, PMID 40156843). These subgroup data support compatibility, not the incremental benefit of randomising combination versus either drug alone.

A live PubMed E-utilities search on 2026-08-30 identified observational target-trial emulation of RAASi, SGLT2i and GLP-1RA combinations, with lower adjusted mortality and kidney-event risk under triple therapy; residual confounding means this does not resolve the randomised incremental-benefit question (Casper 2026, PMID 42658186).

Safety controversies and endpoint discipline

Concern Evidence signal Interpretation
Gastrointestinal intolerance Dose-related nausea, diarrhoea and vomiting; more GI events with tirzepatide than dulaglutide Common and persistence-limiting; usually not a serious-event signal
Pancreatitis A 2025 synthesis of 62 RCTs (66,232 participants) found RR 1.44 (95% CI 1.09–1.89), but estimates became nonsignificant when stratified by background-medication use Rare events, short mean follow-up (43.5 weeks) and exclusion of double-zero studies limit inference (Wen 2025, PMID 40988099)
Tirzepatide pancreatitis dose response Nineteen RCTs (15,471 participants) recorded pancreatitis in 0.22%; 10 vs 5 mg RR 0.78 (0.29–2.09), 15 vs 5 mg RR 0.70 (0.27–1.82) No detected dose response, but intervals remain wide (Benny 2026, PMID 41927408)
Gallbladder/biliary disease Twelve tirzepatide RCTs found gallbladder/biliary disease RR 1.52 (1.17–1.98) and cholelithiasis RR 1.67 (1.14–2.44) Rapid weight loss is a competing mediator; no dose response was detected (Gong 2025, PMID 39569606)
Retinopathy Rapid HbA1c reduction can transiently worsen established retinopathy Rate of improvement and baseline eye disease matter
Kidney claims Albuminuria can improve without eGFR benefit, as in exploratory ELIXA analyses Separate albuminuria, eGFR slope and kidney-failure endpoints (Muskiet 2018, PMID 30292589)

Open questions

  • Which patients gain enough absolute cardiorenal benefit to justify lifelong high-cost therapy? (Agarwal 2025, PMID 40813129)
  • What maintenance strategy best prevents weight regain after dose reduction or withdrawal?
  • Are rapid-improvement retinopathy signals preventable by titration or eye-risk stratification? (Marso 2016, PMID 27633186)
  • Will multi-agonists improve hard outcomes beyond established GLP-1RA rather than only weight surrogates?

References

  1. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016. PMID 27295427
  2. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. PMID 27633186
  3. Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes. Lancet. 2019;394:121-130. PMID 31189511
  4. Holman RR, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes. N Engl J Med. 2017. PMID 28910237
  5. Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease. Lancet. 2018;392:1519-1529. PMID 30291013
  6. Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes. N Engl J Med. 2019. PMID 31185157
  7. Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists. Lancet Diabetes Endocrinol. 2019;7:776-785. PMID 31422062
  8. Palmer SC, et al. SGLT-2 inhibitors and GLP-1 receptor agonists: network meta-analysis. BMJ. 2021. PMID 33441402
  9. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly. N Engl J Med. 2021. PMID 34170647
  10. Jastreboff AM, et al. Tirzepatide Once Weekly for Obesity. N Engl J Med. 2022. PMID 35658024
  11. Garvey WT, et al. Tirzepatide for obesity in people with type 2 diabetes. Lancet. 2023. PMID 37385275
  12. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID 37952131
  13. Aronne LJ, et al. Tirzepatide Compared with Semaglutide for Obesity. N Engl J Med. 2025. PMID 40353578
  14. Mann JFE, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017. PMID 28854085
  15. Perkovic V, et al. Semaglutide on CKD in Patients with Type 2 Diabetes. N Engl J Med. 2024. PMID 38785209
  16. Sattar N, et al. Tirzepatide cardiovascular event risk assessment. Nat Med. 2022;28:591-598. PMID 35210595
  17. Riddle MC, et al. Definition and Interpretation of Remission. Diabetes Care. 2021. PMID 34462270
  18. Agarwal A, et al. Cardiovascular, kidney, and weight effects of T2D therapeutics. BMJ. 2025. PMID 40813129
  19. Sun H, et al. IDF Diabetes Atlas prevalence estimates. Diabetes Res Clin Pract. 2022. PMID 34879977
  20. Zinman B, et al. Empagliflozin Cardiovascular Outcomes. N Engl J Med. 2015. PMID 26378978
  21. Perkovic V, et al. Canagliflozin Renal Outcomes. N Engl J Med. 2019. PMID 30990260
  22. Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019. PMID 30415602
  23. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020. PMID 32970396
  24. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117-127. PMID 36331190
  25. Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes: 5-Year Outcomes. N Engl J Med. 2017. PMID 28199805
  26. Pfeffer MA, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373:2247-2257. PMID 26630143
  27. Gerstein HC, et al. Cardiovascular and Renal Outcomes with Efpeglenatide. N Engl J Med. 2021;385:896-907. PMID 34215025
  28. Lam CSP, et al. Efpeglenatide outcomes with and without concomitant SGLT2 inhibition. Circulation. 2022;145:565-574. PMID 34775781
  29. McGuire DK, et al. Oral Semaglutide and Cardiovascular Outcomes. N Engl J Med. 2025;392:2001-2012. PMID 40162642
  30. Marx N, et al. SOUL outcomes according to SGLT2-inhibitor use. Circulation. 2025;151:1639-1650. PMID 40156843
  31. Lee MMY, et al. Cardiovascular and Kidney Outcomes With Long-Acting GLP-1RAs. Diabetes Care. 2025;48:846-859. PMID 40156846
  32. Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide. N Engl J Med. 2025;393:2409-2420. PMID 41406444
  33. Rosenstock J, et al. Tirzepatide monotherapy in type 2 diabetes (SURPASS-1). Lancet. 2021;398:143-155. PMID 34186022
  34. Dahl D, et al. Tirzepatide added to insulin glargine (SURPASS-5). JAMA. 2022;327:534-545. PMID 35133415
  35. Muskiet MHA, et al. Lixisenatide and renal outcomes in ELIXA. Lancet Diabetes Endocrinol. 2018;6:859-869. PMID 30292589
  36. Casper J, et al. Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Type 2 Diabetes Using Real-World Data. Nephrol Dial Transplant. 2026. PMID 42658186
  37. Wen J, et al. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2025;8:e70113. PMID 40988099
  38. Benny O, et al. Dose-response analysis of tirzepatide and acute pancreatitis: an international systematic review and quantitative meta-analysis of randomised trials. Pancreatology. 2026;26:552-565. PMID 41927408
  39. Gong J, et al. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: a meta-analysis. J Diabetes Investig. 2025;16:83-92. PMID 39569606